Covidien Pure-Play: Pharma Spinoff In The Works
This article was originally published in The Gray Sheet
Executive Summary
Covidien says it has been working for several years toward separating out its pharma business from its larger and more profitable devices/supplies division.
You may also be interested in...
Covidien Completes Pharma Spinoff, Hears From Tyco On Tax Matter
Covidien is now a $9.9 billion, pure-play medical device and supplies company. Separately, the firm could be liable for more than $1 billion in back taxes due to an IRS audit of its former parent, Tyco, though the case is expected to take years to play out in court.
Financings Of The Fortnight Sees A Venture Capital Trend: Identify And Bring In The Buyer Early
Plus news on recent financings by Ember Therapeutics, Aviir, Covidien and Ariad Pharmaceuticals.
Covidien Aims To Double Sales In Emerging Markets By 2017
Covidien plans to double its sales in emerging markets, primarily China and India, to $2 billion over the next five to six years, CEO Jose E. Almeida said during the firm’s Sept. 8 investor meeting in New York.